Neurocrine expects INGREZZA sales to reach up to $2.8B in 2026 amid CRENESSITY launch momentum
Source: SeekingAlpha
2026-02-11 20:15:13 ET
More on Neurocrine Biosciences
- Neurocrine Biosciences, Inc. (NBIX) Q4 2025 Earnings Call Transcript
- Neurocrine Biosciences, Inc. 2025 Q4 - Results - Earnings Call Presentation
- Neurocrine Biosciences, Inc. (NBIX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Neurocrine Biosciences Non-GAAP EPS of $1.88 misses by $0.42, revenue of $805.5M beats by $16.2M
- Neurocrine Biosciences Q4 2025 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
Neurocrine expects INGREZZA sales to reach up to $2.8B in 2026 amid CRENESSITY launch momentum
Neurocrine Biosciences Inc.
NASDAQ: NBIX
NBIX Trading
0.73% G/L:
$128.065 Last:
231,865 Volume:
$128.43 Open:
NBIX Latest News
March 06, 2026 05:00:00 pm
BetterInvesting(TM) Magazine Update on Equifax Inc. (NYSE: EFX) and Neurocrine Bio In. (NASDAQ: NBIX)
February 26, 2026 09:35:00 am
From Lab to Clinic: Five CNS Companies Advancing Neuroscience Treatments
NBIX Stock Data
$13,828,183,256
94,919,824
0.84%
315
N/A
Pharmaceuticals
Healthcare
US
San Diego
